Buechner S A
Department of Dermatology, University of Basel, Switzerland.
J Am Acad Dermatol. 1991 May;24(5 Pt 1):731-4. doi: 10.1016/0190-9622(91)70111-e.
Four patients with basal cell carcinomas were treated with intralesional injections of interferon alfa-2b (1.5 million IU per injection) three times a week for 2 weeks. Histopathologic examination of biopsy specimens of the lesions confirmed the absence of basal cell carcinoma in all cases 4 weeks after completion of therapy. A dense mononuclear cell infiltrate and numerous ectatic blood vessels were present in the dermis at the sites of previous basal cell carcinoma. Immunohistologic analysis of the dermal infiltrate revealed a marked increase of Leu-4+ T cells with a slight predominance of Leu-3+ helper/inducer T cells over Leu-2+ suppressor/cytotoxic T cells. Most of the dermal infiltrate expressed HLA-DR antigen. In addition, Leu-11+ natural killer cells were observed in the dermal infiltrate. Immunohistologic changes in the skin lesions at the sites of previous basal cell carcinoma suggest that intralesional interferon alfa-2b acts on tumor cells by enhancement of local T-cell-mediated immune responses.
4例基底细胞癌患者接受皮损内注射干扰素α-2b（每次注射150万国际单位）治疗，每周3次，共2周。治疗结束4周后，对皮损活检标本进行组织病理学检查，结果证实所有病例均无基底细胞癌。先前基底细胞癌部位的真皮层出现密集的单核细胞浸润和大量扩张的血管。对真皮浸润进行免疫组织学分析显示，Leu-4+ T细胞显著增加，Leu-3+辅助/诱导性T细胞略多于Leu-2+抑制/细胞毒性T细胞。大部分真皮浸润细胞表达HLA-DR抗原。此外，在真皮浸润中观察到Leu-11+自然杀伤细胞。先前基底细胞癌部位皮肤病变的免疫组织学变化表明，皮损内注射干扰素α-2b通过增强局部T细胞介导的免疫反应作用于肿瘤细胞。
